Activated protein C resistance as measured by residual factor v after Russell's Viper Venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 5, 2011, Pages 420-423

  Zangari, Maurizio ^a   Berno, Tamara ^b   Zhan, Fenghuang ^a   Boucher, Kenneth M ^c   Tricot, Guido ^a   Fink, Louis ^d  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF UTAH   (United States)

^d NEVADA CANCER INSTITUTE   (United States)

Author keywords

activated protein C resistance; monoclonal gammopathy of undetermined significance; multiple myeloma

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; FIBRINOGEN; PROTEIN C; PROTHROMBIN; SNAKE VENOM;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MUTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; SNAKE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PROTEIN C; RETROSPECTIVE STUDIES; RUSSELL'S VIPER; VENOUS THROMBOEMBOLISM; VIPER VENOMS;

EID: 79960696897     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283464f6a     Document Type: Article

References (30)

1. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27:4848-4857
2. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 (23 Suppl 1):117-121
3. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87:575-579 (Pubitemid 34302943)
4. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722 (Pubitemid 40216041)
5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846-1850 (Pubitemid 32104130)
6. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558-566 (Pubitemid 38970607)
7. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009; 123:679-686
8. Cohen Al, Sarid R. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res 2010; 125:216-219
9. Kristinsson SY, Fears TR, Gridley G, Turesson I, Meelqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112:3582-3586
10. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008 (Pubitemid 23053939)
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67 (Pubitemid 24144355)
12. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134
13. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost 2010; 8:445-453
14. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276 (Pubitemid 29076142)
15. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130:643-650 (Pubitemid 29196198)
16. Osterud B, Robertsen R, Asvang G, Thijssen BF. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 1994; 5:853-854 (Pubitemid 24366385)
17. Henkens CM, Bom AV, Seinen JA, van der Meer JJ. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 1995; 73:402-404
18. Hampton KK, Preston FE, Greaves M. Resistance to activated protein C. N Engl J Med 1994; 331:130
19. Munoz-Rodriguez FJ, Reverter JC, Font J, Tassies D, Espinosa G, Cervera R, et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus 2002; 11:730-735 (Pubitemid 35408078)
20. De Lucia D, De Vita F, Orditura M, Renis V, Belli A, Conte M, et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 1997; 83:948-952 (Pubitemid 28090598)
21. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated- protein-C resistance in cancer patients. Haemostasis 1997; 27:112-118 (Pubitemid 27368568)
22. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13:187-192 (Pubitemid 35001883)
23. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-96 (Pubitemid 32126427)
24. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29:275-282
25. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122:465-470 (Pubitemid 36951632)
26. Dean CB, Nielsen JD. Generalized linear mixed models: a review and some extensions. Lifetime Data Anal 2007; 13:497-512
27. Gennari LC, Blanco AN, Dominguez MP, Grosso SH, Lazzari MA. Endogenous or exogenous coagulation factor level and the response to activated protein C. Thromb Res 2006; 118:269-273 (Pubitemid 43816673)
28. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134:399-405 (Pubitemid 44079553)
29. Herskovits AZ, Lemire SJ, Longtine J, Dorfman DM. Comparison of Russell Viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C. Am J Clin Pathol 2008; 130:796-804
30. Schoni R, Quehenberg P, Wu JR, Wilmer M. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APCR Factor V Leiden) at two centers -in Europe and USA. Thromb Res 2007; 119:17-26 (Pubitemid 44716212)